We welcome your comments on New Europe's articles and posts. It is our hope that you will use this forum to interact with other readers around the world. In order to keep this experience interesting, we ask you to follow the rules outlined in the terms and conditions.
By submitting comments, you are consenting to these terms and conditions. While NEW EUROPE encourages discussion on all subjects, including sensitive ones, the comments posted are solely the views of those submitting them. NEW EUROPE does not necessarily endorse or agree with the ideas, views, or opinions voiced in these comments.
NEW EUROPE welcomes constructive discussion but discourages the use of copy-pasted materials, unaccompanied links and one-line slogans. This is a moderated forum.Comments deemed abusive, offensive, or those containing profanity may be edited or not be published.
The European Political Newspaper
National News
Spanish firm Almirall and BioFocus enter research alliance
Almirall, S.A., a Barcelona-based international pharmaceutical company, announced that it has formed a research alliance with BioFocus, an affiliate from Belgium-based mid-size biotechnology company, Galapagos NV.
The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Spanish firm Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort.
The value of this collaboration to BioFocus could reach €7.5 million. “We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.
“We are delighted to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies,” added Dr. Chris Newton, SVP Galapagos Services and Managing Director, BioFocus. Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas where the company is especially engaged to offer new therapeutic solutions.
Taxonomy
More in National News
1 of 2
New Europe Headlines
1 of 3
Most Commented